<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408873</url>
  </required_header>
  <id_info>
    <org_study_id>I0113</org_study_id>
    <nct_id>NCT03408873</nct_id>
  </id_info>
  <brief_title>CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)</brief_title>
  <official_title>Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martha Sajatovic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study using customized adherence enhancement (CAE) and long-acting
      injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for
      treatment non-adherence. The CAE approach is expected to improve treatment adherence, as well
      as improve BD symptoms, functioning and treatment attitudes among subjects with bipolar
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral Abilify (aripiprazole) is effective in the treatment of patients with BD when prescribed
      as an acute anti-manic agent and for the maintenance treatment of bipolar disorder. Abilify
      Maintena is an intramuscular (IM) depot formulation of oral aripiprazole (Abilify). Abilify
      Maintena appears to be as effective as standard oral Abilify and may maximize patient
      adherence. Recent clinical trials suggest that Abilify Maintena is effective for the
      treatment of patients with BD.

      Customized Adherence Enhancement (CAE) is a brief behavioral intervention that improves
      adherence approximately 30% more than an educational control in adults with BD. The CAE
      program is a brief, practical intervention consisting of a series of up to four psychosocial
      treatment modules based upon an adult's unique adherence barriers: 1) Psychoeducation on BD
      Medications; 2) Communication with Providers; 3) Strategies to Enhance Medication Routines;
      and 4) Targeting Substance Use Problems with Modified Motivational Enhancement Therapy.
      Multiple studies conducted by these investigators has shown that CAE is effective in in
      treating poorly adherent BD adults.

      In addition, studies by these investigators have shown that combining LAI + CAE dramatically
      improves adherence, symptoms and functional outcomes in people with schizophrenia and
      schizoaffective disorder. In summary, LAI can maximize medication adherence, while CAE
      addresses individual barriers to sustained adherence and behavioral change. Combining LAI +
      CAE improves adherence, symptoms and functioning in high-risk people with primary psychotic
      disorders. The proposed project will test the efficacy of combining Abilify Maintena with CAE
      to help improve outcomes in poorly adherent patients with BD. Pilot data suggest that
      adherence with concomitantly prescribed psychotropic drugs improves with LAI + CAE. The
      findings have particular relevance to BD because many BD patients are on concomitant oral
      psychotropic drugs in addition to antipsychotic. Thus, it is expected that combining CAE with
      LAI will lead to a &quot;halo effect&quot; in that these BD patients will engage in their own care more
      broadly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tablets Routine Questionnaire (TRQ, Past Week)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Treatment non-adherence is measured as a percentage of medications not taken within the past week at time of assessment.
The minimum score is 0 and the maximum score is 100. A higher score implies poorer treatment adherence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tablets Routine Questionnaire (TRQ, Past Month)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Treatment non-adherence is measured as a percentage of medications not taken within the past month at time of assessment.
The minimum score is 0 and the maximum score is 100. A higher score implies poorer treatment adherence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LAI Injection Adherence</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>LAI injection adherence will be determined as a proportion of LAI injections received at the appropriate time (within 7 days of scheduled time).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Brief Psychiatric Rating Scale (BPRS) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The BPRS measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. The minimum score is 18 and the maximum score is 126. A higher score implies a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Young Mania Rating Scale (YMRS) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The YMRS measures symptoms of mania. The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery Asberg Rating Scale (MADRS) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The MADRS measures symptoms of depression. The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impressions (CGI) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The minimum possible score is 1 and the maximum score is 7. A higher score implies a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Drug Attitude Inventory (DAI) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>DAI-10 scoring ranges from -10 to +10 with a total score &gt;0 indicating a positive attitude toward psychiatric medications and a total score of &lt;0 indicating a negative attitude toward psychiatric medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Attitude towards Medication Questionnaire (AMSQ) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The AMSQ comprises 19 items grouped into 7 subscales: general opposition to prophylaxis (4 items), denial of therapeutic effectiveness (2 items), fear of side effects (2 items), difficulty with medication routines (4 items), denial of illness severity (3 items), negative attitudes toward drugs in general (3 items), and lack of information about psychiatric medication (1 item). Higher scores on each subscale represent more negative attitudes toward mood stabilizers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social and Occupational Functioning Assessment Scale (SOFAS) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The SOFAS measures social and occupational functioning independent of the overall severity of the individual's psychological symptoms. The minimum score is 0 and the maximum score is 100. A higher rating implies a higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Assessment of Functioning (GAF) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The minimum score is 1 and the maximum score is 100. A higher score implies higher functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxford Bipolar Knowledge Questionnaires (OBQ) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The OBQ assess knowledge of BD management. Total score rangers from 0-80, with a higher score indicative of better knowledge of bipolar mood management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The Self-Report Habit Index (SRHI) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The SRHI is a measure of habit strength. The minimum score is 12 and the maximum score is 84. A higher score implies stronger habits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Communication Styles Scale score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The Communication Styles Scale is a measure of the impact of physician communication style on medication beliefs and adherence behavior. Total scores range from 0-27 where the higher score indicates a more initial collaborative communication style.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES 8A) score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The SOCRATES measures motivation to reduce the use of substances. The minimum score is 10 and the maximum score is 50. A higher score indicates a higher desire to reduce drinking.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Medication Adherence</condition>
  <condition>Medication Non Adherence</condition>
  <arm_group>
    <arm_group_label>Patient Noncompliance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abilify Maintena</intervention_name>
    <description>Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.</description>
    <arm_group_label>Patient Noncompliance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Customized Adherence Enhancement (CAE)</intervention_name>
    <description>CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).</description>
    <arm_group_label>Patient Noncompliance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals age 18 and older with BD Type 1 or 2 as confirmed by the Mini
             International Psychiatric Inventory (MINI).

          2. Known to have medication treatment adherence problems as identified by the Treatment
             Routines Questionnaire (TRQ, 20% or more missed medications in past week or past
             month)

          3. Screening BPRS score of â‰¥ 36

          4. Ability to be rated on psychiatric rating scales.

          5. Willingness to take LAI

          6. Currently in treatment or scheduled to receive treatment at a Community Mental Health
             Clinic (CMHC) or other clinical setting able to provide mental health care during and
             after study participation

          7. Able to provide written, informed consent to study participation.

        Exclusion Criteria:

          1. Individuals on LAI immediately prior to study enrollment.

          2. Individuals with known intolerance or resistance to either oral aripiprazole or LAI
             formulation of aripiprazole

          3. Prior or current treatment with clozapine

          4. Medical condition or illness, which in the opinion of the research psychiatrist, would
             interfere with the patient's ability to participate in the trial

          5. Physical dependence on substances (alcohol or illicit drugs) likely to lead to
             withdrawal reaction during the course of the study in the clinical opinion of the
             treated research psychiatrist

          6. Immediate risk of harm to self or others

          7. Female who is currently pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Sajatovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Klein</last_name>
    <phone>1-888-819-0004</phone>
    <email>Peter.Klein@UHhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Cassidy</last_name>
    <phone>1-888-819-0004</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martha Sajatovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Levin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Lytle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Ramirez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis Tatsuoka, OhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Martha Sajatovic</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Antipsychotic Drugs</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Injectables</keyword>
  <keyword>Long Acting Injectable Antipsychotic</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Medication Non-Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

